Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Receives $5.5M from Stock Sale

NEW YORK, May 4 (GenomeWeb News) - Tripos said today that Boston-based Midwood Capital has purchased 1.8 million shares of its convertible preferred stock, representing about 18 percent of the company's stock on an as-converted basis, for about $5.5 million.

 

Midwood bought the stock at $3 per share, and also received 550,000 five-year common stock warrants that can be exercised at $3.50, the statement said.

 

The company's shares closed at $2.91 yesterday.

 

Tripos' convertible preferred stock bears a dividend at an annual rate of 10.5 percent and is redeemable in two years, the company said.

 

Seven Hills Partners acted as the placement agent for the transaction. Tripos retained the financial advisory firm in January.

 

Tripos said it is continuing to work with Seven Hills to enhance the growth of its research and informatics businesses.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.